Latest articles by Rupert Hargreaves
-
The markets say sell, but should investors listen?
Analysis As fear grips markets around the world, investors need to have an honest conversation about what they’re comfortable with owning.
Analysis -
Is Gulf Keystone Petroleum’s 20% yield worth chasing?
Analysis The Gulf Keystone Petroleum share price has some attractive qualities, but investors need to tread carefully.
Analysis -
Despite surging profits investors should avoid Centrica shares
Tips Profits in the energy sector are booming but Centrica shares are struggling. Rupert Hargreaves explains why he’d avoid the stock.
Tips -
5 buys: MoneyWeek’s best dividend ETFs
Tips Exchange traded funds (ETFs) have only been around for three decades, but they have proved hugely popular, combining flexibility and low cost. Here, Rupert Hargreaves picks the five highest-yielding ETFs on the market now.
Tips -
Five dividend stocks to beat inflation
Tips Rupert Hargreaves looks at five stocks to beat inflation that should help protect your wealth
Tips -
How to invest today? Look to the past, not the future
Analysis The past few years have seen so many changes to our way of life that many people said we had entered a “new normal”. But as it turns out, the new normal looks a lot like the old normal, says Rupert Hargreaves. Here’s what to buy now.
Analysis -
Cineworld faces a bleak future – investors should stay away
Analysis Weighed down by crippling debts and with consumers tightening their belts, Cineworld's future does not look bright, says Rupert Hargreaves. Investors should steer well clear.
Analysis -
Britain’s ten most-hated shares – w/e 12 August
News Rupert Hargreaves looks at Britain's ten most-hated shares, and what short-sellers are looking at now.
News -
Britain’s most-bought shares w/e 12 August
News A look at Britain’s most-bought shares as of 12 August, providing an insight into how investors are thinking and where opportunities may lie.
News -
Are GSK’s legal troubles a threat to the firm’s survival?
Analysis Pharmaceutical giant GlaxoSmithKline is facing legal action over heartburn drug Zantac that has seen billions wiped off its market value. Rupert Hargreaves looks at how it might affect the business's prospects.
Analysis -
Are UK house prices set to fall? It’s not so simple
Analysis Figures suggest UK house prices are starting to slide, but we shouldn’t take these numbers at face value, explains Rupert Hargreaves.
Analysis -
Aviva: One for income investors to tuck away
Tips Insurance giant Aviva is one of the highest yielding stocks in the FTSE 100 – and it’s cheap, too, making it a tempting target for income investors. Rupert Hargreaves delves into the numbers.
Tips -
Director dealings w/e 5 August: what company insiders are buying and selling
News Directors’ share dealings can often give investors an insight into the sentiment of company insiders. Here are some of the biggest deals by company directors for the week ending 5 August.
News -
Is abrdn’s eye-catching 9.2% dividend yield sustainable?
Tips Shares in investment manager abrdn currently yield 9.2%. Generally speaking, says Rupert Hargreaves, it pays to be sceptical of very high dividend yields. So is that the case here, or is abrdn one for income investors to tuck away?
Tips -
Why you need to invest at least some of your money outside the UK
Advice Most investors tend to have a bias to their home market. But that’s a mistake, says Rupert Hargreaves. Investing in international stocks can help diversify your portfolio and protect your wealth from unnecessary risks.
Advice -
Frasers is showing the rest of the retail world how it’s done
Tips Frasers Group – formerly known as Sports Direct – is a company many people love to hate. But its policy of judicious acquisitions and its move upmarket have proved to be a huge success and profits are booming, says Rupert Hargreaves.
Tips -
Royal Mail’s 7.2% dividend yield is now under threat
Tips Royal Mail's dividend yield is coming under pressure as costs rise and delivery volumes fall. Profits are under threat, and investors can't take anything for granted, says Rupert Hargreaves.
Tips -
How Wise is profiting by slashing foreign exchange costs
Tips Wise – formerly known as Transferwise – is a fast-growing disruptor in the fragmented foreign-exchange market. It’s doing very well for itself, says Rupert Hargreaves, and there’s plenty of scope for growth.
Tips -
Should you invest in Glaxo spin-off Haleon?
Tips Pharmaceutical giant GlaxoSmithKline has finally spun-out its consumer health arm, Haleon. Rupert Hargreaves looks at the new business and asks, should you buy Haleon shares?
Tips -
I love its cars, but I wouldn’t touch Aston Martin’s shares
Tips Aston Martin makes beautiful cars. But it has a chequered history and continues to lurch from disaster to disaster. That’s why I wouldn’t buy Aston Martin shares, says Rupert Hargreaves.
Tips -
Five London-listed stocks to play the coming oil shortage
Tips After peaking in June, the oil price has fallen back and oil companies have fallen out of favour with investors. But with supply predicted to outstrip demand, there are plenty of opportunities to profit. Here, Rupert Hargreaves picks five of the best London-listed oil stocks to buy now.
Tips -
Five real estate investment trusts for income and inflation protection
Tips Real estate investment trusts (Reits) are a good way to earn income from property. Here, Rupert Hargreaves picks five of the best to buy now.
Tips -
Phoenix Group’s 8.5% dividend yield looks here to stay
Tips At a forecast 8.5%, Financial services group Phoenix, has one of the highest dividend yields in the FTSE 100. And it has all the hallmarks of a great income play, says Rupert Hargreaves.
Tips -
The highest-yielding Pibs and preference shares
Tips As well as ordinary shares, companies and other institutions issue preference shares and permanent interest-bearing shares (Pibs), which act more like fixed income securities. Rupert Hargreaves explains everything you need to know, and lists the highest-yielding Pibs and preference shares on the market.
Tips
